Related Experiment Video

Updated: Jul 11, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy

Laura Smith1, Michael J Lind, Philip J Drew

  • 1Cancer Biology Proteomics Group, Postgraduate Medical Institute of the University of Hull, UK.

European Journal of Cancer (Oxford, England : 1990)
|September 25, 2007
PubMed

Insights

The ubiquitin/proteasome pathway is crucial in cancer. Proteasome inhibitors show promise in cancer treatment and may enhance chemotherapy and radiotherapy effectiveness, though their role in treatment resistance requires further investigation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The ubiquitin/proteasome (UP) pathway is vital for cellular protein homeostasis.
  • Dysregulation of the UP pathway is implicated in various human diseases, notably cancer.
  • Proteasome inhibition is an established therapeutic strategy for multiple myeloma and is explored for other cancers.

Purpose of the Study:

  • To review the multifaceted roles of the ubiquitin/proteasome pathway in cancer.
  • To discuss the therapeutic implications of proteasome inhibition in oncology.
  • To explore the conflicting evidence regarding the UP pathway's involvement in anticancer treatment resistance.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of research on proteasome inhibitors in various cancer types.
  • Synthesis of data on the UP pathway's influence on therapeutic response.

Main Results:

  • Proteasome inhibition demonstrates efficacy in hematological malignancies and solid tumors.
  • Evidence suggests proteasome inhibition can sensitize cancer cells to chemotherapy and radiotherapy.
  • Contradictory findings exist regarding the UP pathway's role in mediating resistance to cancer treatments.

Conclusions:

  • The ubiquitin/proteasome pathway is a significant target in cancer therapy.
  • Proteasome inhibitors hold potential for combination therapies to overcome treatment resistance.
  • Further research is needed to fully elucidate the complex roles of the UP pathway in cancer treatment outcomes.

More Related Videos

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations10:26

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations

Published on: November 7, 2019

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...